Fluorescent in Situ Hybridization (FISH)

Global Fluorescent in Situ Hybridization (FISH) Market to Reach US$1.6 Billion by 2030

The global market for Fluorescent in Situ Hybridization (FISH) estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$898.1 Million by the end of the analysis period. Growth in the Instrument segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$313.4 Million While China is Forecast to Grow at 9.1% CAGR

The Fluorescent in Situ Hybridization (FISH) market in the U.S. is estimated at US$313.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$325.2 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Fluorescent In Situ Hybridization (FISH) Market – Key Trends & Drivers Summarized

Why Is FISH Technology Gaining Prominence in Molecular Diagnostics?

Fluorescent in situ hybridization (FISH) has emerged as a cornerstone of molecular diagnostics, owing to its high specificity, sensitivity, and visual clarity in detecting genetic abnormalities at the chromosomal level. Unlike conventional cytogenetic methods, FISH utilizes fluorescent probes that bind directly to specific DNA sequences, enabling the visualization of structural and numerical chromosomal changes in both metaphase and interphase cells. This technology allows clinicians and researchers to identify chromosomal translocations, gene amplifications, deletions, and other abnormalities with a level of precision that is crucial for diagnosing a wide range of genetic disorders and malignancies. In cancer diagnostics, FISH is particularly vital in identifying specific genetic markers for personalized treatment regimens—such as HER2 amplification in breast cancer or ALK rearrangements in non-small cell lung cancer. Its ability to provide spatial context within intact cells makes it indispensable in tissue biopsies, where it can detect heterogeneity within tumor samples. Moreover, the non-radioactive nature of FISH, combined with its relatively rapid turnaround time compared to traditional karyotyping, has made it a preferred tool in clinical cytogenetics, prenatal screening, and hematologic oncology. As precision medicine continues to evolve, FISH is gaining further traction due to its role in stratifying patients for targeted therapies, monitoring disease progression, and verifying minimal residual disease—all of which make it increasingly vital to modern clinical workflows.

How Are Clinical Applications Expanding Across Diverse Disease Landscapes?

FISH technology is seeing broader clinical applications beyond its traditional stronghold in oncology, as its adaptability and accuracy drive its use across a wider range of disease conditions and healthcare settings. In prenatal and postnatal diagnostics, FISH plays a central role in detecting chromosomal abnormalities such as trisomies (e.g., Down syndrome, Edwards syndrome) and microdeletions (e.g., DiGeorge syndrome), particularly when rapid results are necessary. In hematological malignancies like leukemia and lymphoma, FISH enables the detection of gene fusions (e.g., BCR-ABL in chronic myeloid leukemia), providing diagnostic confirmation and guiding therapeutic decisions. Its utility extends to fertility assessments, where it is employed in analyzing sperm aneuploidy and embryo screening during in vitro fertilization (IVF). Moreover, FISH is being increasingly utilized in solid tumor profiling, including prostate, bladder, and gastric cancers, where identifying specific chromosomal aberrations can help in predicting disease aggressiveness and therapeutic response. The rise of companion diagnostics, in which molecular assays are paired with specific drug therapies, has also elevated the clinical significance of FISH. Regulatory agencies and healthcare providers are placing greater emphasis on diagnostic precision, further entrenching FISH into clinical protocols. Additionally, veterinary medicine and agricultural genetics are exploring FISH-based tools for genomic analysis in animals and plants, showcasing its cross-disciplinary versatility. These expanding applications are not only increasing the demand for FISH kits and reagents but also encouraging laboratories and hospitals to invest in infrastructure and training to support high-quality cytogenetic testing.

How Are Technological Advancements Enhancing the Utility and Accessibility of FISH?

Recent technological innovations are significantly enhancing the performance, automation, and scalability of FISH, making it more accessible and efficient for both research and clinical diagnostics. One of the most notable advancements is the development of multiplex FISH techniques, which allow simultaneous visualization of multiple genetic targets using a range of fluorophores. This has greatly improved the throughput and interpretability of complex genomic rearrangements, especially in cancer studies. Automated image analysis and digital pathology platforms are also revolutionizing how FISH results are interpreted, minimizing human error and enabling remote diagnostics through cloud-based data sharing. Innovations in probe design—including peptide nucleic acid (PNA) probes and locked nucleic acid (LNA) probes—are improving hybridization efficiency and signal stability, even in challenging samples such as formalin-fixed, paraffin-embedded tissues. Moreover, the integration of FISH with other molecular tools like immunohistochemistry (IHC) and next-generation sequencing (NGS) is offering a multi-dimensional view of genomic and proteomic alterations, enhancing diagnostic and prognostic insights. The introduction of ready-to-use FISH kits, standardized protocols, and automation-compatible platforms is reducing the technical barriers associated with the procedure, enabling wider adoption across medium- and small-sized laboratories. In addition, miniaturization and cost optimization of FISH workflows are aligning with global trends in decentralized and point-of-care diagnostics. These innovations are not only elevating the accuracy and reliability of FISH but also facilitating its incorporation into routine screening programs and personalized medicine pipelines.

What Factors Are Driving the Growth of the Global FISH Market?

The growth in the fluorescent in situ hybridization (FISH) market is driven by several factors rooted in technological advancements, expanding clinical indications, evolving healthcare demands, and institutional support for precision diagnostics. A major growth driver is the rising global burden of cancer and genetic disorders, which necessitates more sensitive and rapid diagnostic techniques. As the demand for early and accurate detection rises, FISH is being increasingly adopted in oncology diagnostics to support personalized treatment decisions, particularly in solid tumors and hematologic malignancies. The expanding role of genetic testing in reproductive health, prenatal care, and fertility assessments is also boosting demand for FISH-based diagnostics. Furthermore, the integration of FISH into companion diagnostics for targeted therapies is reinforcing its value in clinical decision-making. The growing adoption of laboratory automation and digital pathology systems is making FISH more scalable and efficient, supporting its use in both high-throughput and low-resource settings. Institutional support through government funding, research grants, and regulatory approvals is enabling the development of advanced FISH assays and infrastructure. Additionally, the shift toward value-based healthcare and patient-specific treatment plans is accelerating the uptake of precision diagnostic tools like FISH. The emergence of new markets in Asia-Pacific, Latin America, and the Middle East—fueled by improvements in healthcare infrastructure and increasing awareness of genetic diseases—is expanding the global footprint of FISH technology. Together, these factors are creating a strong and sustained demand for FISH in research and diagnostics, positioning it as a critical tool in the genomic era.

SCOPE OF STUDY:

The report analyzes the Fluorescent in Situ Hybridization (FISH) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Consumables, Instrument, Software); Technology (DNA Fluorescent In Situ Hybridization, RNA Fluorescent In Situ Hybridization, PNA Fluorescent In Situ Hybridization, Other Technologies); Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, Other Applications); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Organizations, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Abcam plc
• Abnova Corporation
• Advanced Cell Diagnostics, Inc.
• Agilent Technologies Inc.
• Bio SB Inc.
• BioCare Medical, LLC
• BioDot Inc.
• BioGenex Laboratories, Inc.
• Bio-View Ltd
• Cytocell Ltd
• Enzo Biochem Inc.
• F. Hoffmann-La Roche Ltd
• Genemed Biotechnologies, Inc.
• Leica Biosystems Nussloch GmbH
• Merck KGaA
• MetaSystems Probes GmbH
• PerkinElmer Inc.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.